As the new president of the Association of American Cancer Institutes, Roy Jensen will focus on public policy at the state and local level as his presidential priority.
Anne-Marie Langevin, of the South Texas Pediatric Minority/Underserved NCI Community Oncology Research Program site in San Antonio, won the 2018 Harry Hynes Award, which is given annually to the PI who reflects the outstanding contribution to clinical trials and community research.
Matthew Ong spoke with Richard Goldberg.
Matthew Ong spoke with John Stewart.
Intricate deception went into luring NIH Director Francis Collins onto Sacha Baron Cohen's television show.
Researchers at Project GENIE, the largest publicly available genomic database in the U.S., understand what it takes to convert sequencing data into real-world evidence: a lot of money, manpower, and data harmonization, said Shawn Sweeney, director of the American Association for Cancer Research Project GENIE Coordinating Center.
Agios Pharmaceuticals Inc., the sponsor of two drugs that may change the outcomes for a subset of acute myelogenous leukemia patients, is focused on more than AML.
As the landscape in acute myelogenous leukemia changes, consultations with top-tier experts have become a necessity, said John Byrd, the principal investigator of Beat AML, Distinguished University Professor, the D. Warren Brown Professor of Leukemia Research at The Ohio State University, a member of the NCI Leukemia Steering Committee, chair of the Leukemia and Correlative Science Committee within the Alliance for Clinical Trials in Oncology.
As a veteran of the FDA Oncologic Drugs Advisory Committee, Maha Hussain took part in the group's past discussions on treatment options for men with non-metastatic castration-resistant prostate cancer.
The endpoint of metastasis-free survival is unlikely to be used in settings beyond non-metastatic castration-resistant prostate cancer, said Julia Beaver, director of Division of Oncology Products 1 at the FDA Center for Drug Evaluation and Research.
